G1 is developing three new oncology therapies that are currently in clinical trials
G1 has three clinical-stage programs, trilaciclib, rintodestrant (G1T48) and lerociclib, that are designed to improve patient outcomes for those affected by cancer. To learn more about our clinical trials, please visit www.clinicaltrials.gov or contact us at firstname.lastname@example.org.
Patients and families should speak to their physician about risks and benefits of a clinical trial and to ask whether a study is right for them.
Trilaciclib is a first-in-class FDA-designated "Breakthrough Therapy" designed to improve outcomes for people with cancer who are treated with chemotherapy. Trilaciclib is currently being studied in small cell lung cancer and triple-negative breast cancer. At this time, we have completed enrollment for our trilaciclib clinical trials and are not recruiting patients for our ongoing trials. We plan to begin additional trials in colorectal cancer and neoadjuvant breast cancer in 2020.
Rintodestrant (G1T48) is a potential best-in-class oral selective estrogen receptor degrader (SERD) being studied as monotherapy or in combination with other targeted therapies to treat estrogen receptor-positive (ER+) breast cancer. We are currently recruiting women with ER+, HER2-negative advanced breast cancer for a Phase 1/2 trial assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of rintodestrant (G1T48). For more information, please visit www.clinicaltrials.gov (Identifier: NCT03455270).
Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in types of breast and lung cancer. It is currently being studied in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer and epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer. At this time, we have completed enrollment and are not recruiting patients for our ongoing trials.